Single arm and open-label study evaluating the effect of fucoidan intake on proviral load in carriers with human T-cell leukemia virus type-I
Not Applicable
- Conditions
- Human T-cell leukemia virus type-I (HTLV-1) infection
- Registration Number
- JPRN-UMIN000027358
- Lead Sponsor
- niversity of the Ryukyus
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1. Those who have developed HTLV-1 associated diseases (ATL, HAM/TSP, HU) 2. Those who suffered any other malignant tumor and receive medical treatment 3. Those who suffer from systemic infection 4. Those who receive medical treatment that might affect HTLV-1 proviral load
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HTLV-1 proviral load (real-time PCR method)
- Secondary Outcome Measures
Name Time Method fucoidan concentration in urine (ELISA), Immune function (flow cytometric analysis of cell surface marker)